The DOI matches its Crossref record.
The clinical landscape for SMA in a new therapeutic era
Open accessAbstract
Despite significant advances in basic research, the treatment of degenerative diseases of the nervous system remains one of the greatest challenges for translational medicine. The childhood onset motor neuron disorder spinal muscular atrophy (SMA) has been viewed as one of the more tractable targets for molecular therapy due to a detailed understanding of the molecular genetic basis of the disease. In SMA, inactivating mutations in the SMN1 gene can be partially compensated for by limited expression of SMN protein from a variable number of copies of the SMN2 gene, which provides both a molecular explanation for phenotypic severity and a target for therapy. The advent of the first tailored molecular therapy for SMA, based on modulating the splicing behaviour of the SMN2 gene provides, for the first time, a treatment which alters the natural history of motor neuron degeneration. Here we consider how this will change the landscape for diagnosis, clinical management and future therapeutic trials in SMA, as well as the implications for the molecular therapy of other neurological diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
De Vivo, D. C., Bertini, E., Swoboda, K. J., Hwu, W.-L., Crawford, T. O., Finkel, R. S., Kirschner, J., Kuntz, N. L., Parsons, J. A., Ryan, M. M., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.09.007 · Cited by 629
Calucho, M., Bernal, S., Alías, L., March, F., Venceslá, A., Rodríguez-Álvarez, F. J., Aller, E., Fernández, R. M., Borrego, S., Millán, J. M., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.01.003 · Cited by 497
Self-citation
Metadata
- Authors
- Talbot, K., & Tizzano, E. F.
- Venue
- Gene Therapy
- Published
- 2017-07-23
- Volume
- 24
- Issue
- 9
- Pages
- 529-533
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2671097371
- Cited by
- 174
- References
- 0
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical landscape for SMA in a new therapeutic era. https://app.cochat.ai/papers/10.1038/gt.2017.52
- The paper
- Talbot, K., & Tizzano, E. F. (2017). The clinical landscape for SMA in a new therapeutic era. Gene Therapy. https://doi.org/10.1038/gt.2017.52
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.